EP1153928A4 - 2-methyl-3-butenyl-1-pyrophosphoric acid salts and agents for treating lymphocytes - Google Patents

2-methyl-3-butenyl-1-pyrophosphoric acid salts and agents for treating lymphocytes

Info

Publication number
EP1153928A4
EP1153928A4 EP00900853A EP00900853A EP1153928A4 EP 1153928 A4 EP1153928 A4 EP 1153928A4 EP 00900853 A EP00900853 A EP 00900853A EP 00900853 A EP00900853 A EP 00900853A EP 1153928 A4 EP1153928 A4 EP 1153928A4
Authority
EP
European Patent Office
Prior art keywords
butenyl
methyl
pyrophosphoric acid
agents
acid salts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP00900853A
Other languages
German (de)
French (fr)
Other versions
EP1153928A1 (en
EP1153928B1 (en
Inventor
Yoshimasa Tanaka
Takehiko Uchiyama
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of EP1153928A1 publication Critical patent/EP1153928A1/en
Publication of EP1153928A4 publication Critical patent/EP1153928A4/en
Application granted granted Critical
Publication of EP1153928B1 publication Critical patent/EP1153928B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/50—Colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/098—Esters of polyphosphoric acids or anhydrides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/113—Esters of phosphoric acids with unsaturated acyclic alcohols
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

A pharmaceutically acceptable salt of 2-methyl-3-butenyl-1-pyrophosphoric acid; an agent for treating lymphocytes which comprises at least one of 2-methyl-3-butenyl-1-pyrophosphoric acid, a pharmaceutically acceptable salt thereof, and a hydrate thereof; V gamma 2V delta 2 type T cells treated by the same; and a medicine containing the same specifically stimulate and proliferate the human V gamma 2V delta 2 type T cells, and also induce and enhance an antitumor activity thereof.
EP00900853A 1999-01-21 2000-01-21 2-methyl-3-butenyl-1-pyrophosphoric acid salts and agents for treating lymphocytes Expired - Lifetime EP1153928B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP1334399 1999-01-21
JP1334399 1999-01-21
PCT/JP2000/000273 WO2000043403A1 (en) 1999-01-21 2000-01-21 2-methyl-3-butenyl-1-pyrophosphoric acid salts and agents for treating lymphocytes

Publications (3)

Publication Number Publication Date
EP1153928A1 EP1153928A1 (en) 2001-11-14
EP1153928A4 true EP1153928A4 (en) 2003-04-23
EP1153928B1 EP1153928B1 (en) 2005-12-21

Family

ID=11830482

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00900853A Expired - Lifetime EP1153928B1 (en) 1999-01-21 2000-01-21 2-methyl-3-butenyl-1-pyrophosphoric acid salts and agents for treating lymphocytes

Country Status (7)

Country Link
US (2) US6534050B1 (en)
EP (1) EP1153928B1 (en)
JP (1) JP4025019B2 (en)
AT (1) ATE313547T1 (en)
DE (1) DE60024969T2 (en)
ES (1) ES2254130T3 (en)
WO (1) WO2000043403A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1153928B1 (en) * 1999-01-21 2005-12-21 Chugai Seiyaku Kabushiki Kaisha 2-methyl-3-butenyl-1-pyrophosphoric acid salts and agents for treating lymphocytes
KR100906018B1 (en) * 2001-07-20 2009-07-06 바이오에이전시 아게 Organo-phosphorous compounds for activating gamma/delta t cells
FR2833266B1 (en) * 2001-12-11 2004-10-22 Mayoly Spindler Lab NOVEL PHOSPHONATE DERIVATIVES, THEIR PREPARATION PROCESS AND THEIR USE AS MODULATORS OF THE ACTIVITY OF TGAMMA9 DELTA2 LYMPHOCYTES
ATE441420T1 (en) * 2002-12-02 2009-09-15 Innate Pharma COMPOSITIONS CONTAINING INTERLEUKIN-2 AND GAMMA DELTA T CELL ACTIVATOR AND USES THEREOF
JP4281071B1 (en) 2008-07-10 2009-06-17 学校法人兵庫医科大学 Vγ9Vδ2 T cell proliferating agent, method for producing activated Vγ9Vδ2 T cells and use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2715660A1 (en) * 1994-01-28 1995-08-04 Centre Nat Rech Scient Organophosphorus activating compounds of Tgammadelta lymphocytes, process for preparing and / or isolating and / or characterizing these compounds, compositions and pharmaceutical uses.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639653A (en) * 1993-07-19 1997-06-17 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva Universtiy Method for proliferating Vγ2Vδ2 T cells
EP1153928B1 (en) * 1999-01-21 2005-12-21 Chugai Seiyaku Kabushiki Kaisha 2-methyl-3-butenyl-1-pyrophosphoric acid salts and agents for treating lymphocytes
US6262162B1 (en) * 1999-03-19 2001-07-17 Amcol International Corporation Layered compositions with multi-charged onium ions as exchange cations, and their application to prepare monomer, oligomer, and polymer intercalates and nanocomposites prepared with the layered compositions of the intercalates
CN1317328C (en) * 2000-09-21 2007-05-23 罗姆和哈斯公司 Aqueous nanocomposite dispersions: processes, compositions, and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2715660A1 (en) * 1994-01-28 1995-08-04 Centre Nat Rech Scient Organophosphorus activating compounds of Tgammadelta lymphocytes, process for preparing and / or isolating and / or characterizing these compounds, compositions and pharmaceutical uses.

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BOULLIER SEVERINE ET AL: "Phosphoantigen activation induces surface translocation of intracellular CD94/NKG2A class I receptor on CD94- peripheral Vgamma9 Vdelta2 T cells but not on CD94- thymic or mature gammadelta T cell clones.", EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 28, no. 11, November 1998 (1998-11-01), pages 3399 - 3410, XP002229151, ISSN: 0014-2980 *
BURK MARTIN R ET AL: "Human V-gamma-9-V-delta-2 cells are stimulated in a cross-reactive fashion by a variety of phosphorylated metabolites.", EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 25, no. 7, 1995, pages 2052 - 2058, XP008012991, ISSN: 0014-2980 *
POQUET YANNICK ET AL: "Expansion of Vgamma9Vdelta2 T cells is triggered by Francisella tularensis-derived phosphoantigens in tularemia but not after tularemia vaccination.", INFECTION AND IMMUNITY, vol. 66, no. 5, May 1998 (1998-05-01), pages 2107 - 2114, XP002229149, ISSN: 0019-9567 *
POQUET YANNICK ET AL: "High-pH anion-exchange chromatographic analysis of phosphorylated compounds: Application to isolation and characterization of nonpeptide mycobacterial antigens.", ANALYTICAL BIOCHEMISTRY, vol. 243, no. 1, 1996, pages 119 - 126, XP002229150, ISSN: 0003-2697 *
SCHOEL B ET AL: "Phosphate is essential for stimulation of V.gamma.9V.delta.2 T lymphocytes by mycobacterial low molecular weight ligand", EUROPEAN JOURNAL OF IMMUNOLOGY, WEINHEIM, DE, vol. 24, no. 8, 1994, pages 1886 - 1892, XP002102421, ISSN: 0014-2980 *
TANAKA Y ET AL: "Natural and synthetic non-peptide antigens recognized by human.gamma..delta. T cells", NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 375, 11 May 1995 (1995-05-11), pages 155 - 158, XP002102418, ISSN: 0028-0836 *
TANAKA YOSHIMASA ET AL: "Nonpeptide ligands for human gamma-delta-T cells.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 91, no. 17, 1994, 1994, pages 8175 - 8179, XP002229148, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
US20030152551A1 (en) 2003-08-14
JP4025019B2 (en) 2007-12-19
WO2000043403A1 (en) 2000-07-27
DE60024969T2 (en) 2006-09-07
US6534050B1 (en) 2003-03-18
DE60024969D1 (en) 2006-01-26
ATE313547T1 (en) 2006-01-15
US7094557B2 (en) 2006-08-22
ES2254130T3 (en) 2006-06-16
EP1153928A1 (en) 2001-11-14
EP1153928B1 (en) 2005-12-21

Similar Documents

Publication Publication Date Title
PT1083899E (en) Derivatives of 1-deoxy-galactonojirimycin and their use in the treatment of lysosomal storage diseases by enhancing lysosomal alpha-galactosidase a
TR200000129T2 (en) Brand new spiroazabicyclic heterocyclic compounds.
MY103352A (en) Piperazinyl-heterocyclic compounds
TW376319B (en) Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
GEP20043269B (en) Purine Derivatives, Method for Their Production and Composition Containing the Same
GR3019450T3 (en) Azaheterocyclylmethyl-chromans as agents for the treatment of diseases of the central nervous system
MX9803753A (en) CYCLIC AND HETEROCYCLIC N-SUBSTITUTED 'alpha'-IMINOHYDROXAMIC AND CARBOXYLIC ACIDS.
HK1048313A1 (en) Quinuclidine acrylamides
NZ334124A (en) Use of the chelating agent clioquinol, with vitamin B12 for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease
MX9704030A (en) 2-heterocyclyloxy and thiomethyl-1,2,5-thiadiazolidin-3-one 1,1-dioxides and compositions and method of use thereof.
IL119207A0 (en) Treatment of tinnitus using neuroprotective agents
CZ285522B6 (en) Medicament for reducing concentration of glucose in blood
HUP0103691A3 (en) Use of pyrido[1,2a]pyrazine derivatives for the treatment of parkinson's disease, adhd and microadenomas and medicaments containing them
PH29953A (en) Substituted 4-phenyl-pyridones and 4-phenyl-3-alkoxypyridines
MX9704037A (en) 2-substituted 1,2,5-thiadiazolidin-3-one 1,1-dioxides and compositions and method of use thereof.
NZ513650A (en) Pharmaceutical composition for the treatment of urinary incontinence, motion sickness and vertigo
EP0620004A4 (en) Medicinal composition.
MY103210A (en) Arylpiperazinyl-alkylene-phenyl-heterocyclic compounds.
GEP19991871B (en) Thiol Derivatives with Metallopeptidase Inhibitory Activity
GEP20032914B (en) Derivatives of 1,3,4-Oxadiazolone
EP1006793A4 (en) Anti-arrhythmic composition and methods of treatment
EP1153928A4 (en) 2-methyl-3-butenyl-1-pyrophosphoric acid salts and agents for treating lymphocytes
MX9704034A (en) Substituted 2-arylcarbonyloxymethyl-1,2,5-thiadiazolidin-3-one 1,1-dioxide derivatives and compositions and method of use thereof.
GR3019774T3 (en) Piperidylmethyl substituted chroman derivatives as agents for the treatment of diseases of the central nervous system
TW349864B (en) Use of N-(pyridinyl)-1H-indol-a-amines for the preparation of a medicament for the treatment of obsessive-compulsive disorders

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010806

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIN1 Information on inventor provided before grant (corrected)

Inventor name: UCHIYAMA, TAKEHIKO10-48 HAGIYAMA-CHO 4-CHOME

Inventor name: TANAKA, YOSHIMASAPURIMIERU SHINOZAKI 201

RIC1 Information provided on ipc code assigned before grant

Ipc: 7C 12N 5/06 B

Ipc: 7A 61P 35/00 B

Ipc: 7A 61K 31/66 B

Ipc: 7A 61K 35/14 B

Ipc: 7A 61K 31/661 B

Ipc: 7C 07F 9/113 A

A4 Supplementary search report drawn up and despatched

Effective date: 20030310

17Q First examination report despatched

Effective date: 20030730

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20051221

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20051221

Ref country code: CH

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20051221

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20051221

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20051221

Ref country code: LI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20051221

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060123

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 60024969

Country of ref document: DE

Date of ref document: 20060126

Kind code of ref document: P

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060131

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060131

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060321

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060321

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060321

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060522

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2254130

Country of ref document: ES

Kind code of ref document: T3

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

ET Fr: translation filed
REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20060922

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20051221

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20120113

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20130123

Year of fee payment: 14

Ref country code: GB

Payment date: 20130116

Year of fee payment: 14

Ref country code: FR

Payment date: 20130204

Year of fee payment: 14

Ref country code: DE

Payment date: 20130116

Year of fee payment: 14

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 60024969

Country of ref document: DE

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20140121

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 60024969

Country of ref document: DE

Effective date: 20140801

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140801

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20140930

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140121

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140131

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20150408

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140122

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140121